Progesterone and Src Family Inhibitor PP1 Synergistically Inhibit Cell Migration and Invasion of Human Basal Phenotype Breast Cancer Cells

Mingxuan Xie, Central South University
Li Zhou, Shanghai Seventh Peoples Hosp
Xi Chen, Central South University
Lindsey O. Gainey, Atlanta Research & Educational Foundation
Jian Xiao, Central South University
Mark Nanes, Emory University
Anji Hou, Shanghai Seventh Peoples Hosp
Shaojin You, Atlanta Research & Educational Foundation
Qiong Chen, Central South University

Journal Title: BioMed Research International
Volume: Volume 2015
Publisher: Hindawi Publishing Corporation | 2015-05-17, Pages 426429-426429
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1155/2015/426429
Permanent URL: https://pid.emory.edu/ark:/25593/rxgtc

Final published version: http://dx.doi.org/10.1155/2015/426429

Copyright information:
© 2015 Mingxuan Xie et al.
This is an Open Access work distributed under the terms of the Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/).

Accessed April 11, 2022 11:04 PM EDT
Research Article

Progesterone and Src Family Inhibitor PP1 Synergistically Inhibit Cell Migration and Invasion of Human Basal Phenotype Breast Cancer Cells

Mingxuan Xie,1,2,3 Li Zhou,3,4 Xi Chen,2 Lindsey O. Gainey,3 Jian Xiao,1,2 Mark S. Nanes,5 Anji Hou,4 Shaojin You,3 and Qiong Chen1,2

1Department of Geriatrics, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008, China
2Department of Respiratory, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan 410008, China
3Laboratory of Cancer Experimental Therapy, Atlanta Research & Educational Foundation (ISIF), Atlanta VA Medical Center, 1670 Clairmont Road, Decatur, GA 30033, USA
4Department of Oncology, Shanghai Seventh People’s Hospital, 358 Datong Road, Pudong New District, Shanghai 200137, China
5Medical Service, Atlanta VA Medical Center and Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, Emory University School of Medicine, Decatur, GA 30033, USA

Correspondence should be addressed to Shaojin You; shaojin.you@va.gov and Qiong Chen; qiongch@163.com

Received 10 July 2014; Accepted 19 November 2014

Academic Editor: Sandeep Singh

Copyright © 2015 Mingxuan Xie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Basal phenotype breast cancer is one of the most aggressive breast cancers that frequently metastasize to brain. The role of sex hormones and their receptors in development of this disease is largely unclear. We demonstrated that mPR\(\alpha\) was expressed at a moderate level in a brain metastatic BPBC cell line MB231Br, which was derived from the parent mPR\(\alpha\) undetectable MB231 cells. It functioned as an essential mediator for progesterone induced inhibitory effects on cell migration of MB231Br and, when coincubated with PP1, synergistically enhanced the progesterone 's inhibitory effect on cell migration and invasion in vitro. Progesterone and PP1 cotreatment induced a cascade of molecular signaling events, such as dephosphorylation of FAK, downregulation of MMP9, VEGF, and KCNMA1 expressions. Our in vitro study demonstrated that mPR\(\alpha\) was expressed and functioned as an essential mediator for progesterone induced inhibitory effects on cell migration and invasion in BPBC cells. This inhibitory effect was enhanced by PP1 via FAK dephosphorylation, MMP9, VEGF, and KCNMA1 downregulation mechanisms. Our study provides a new clue toward the development of novel promising agents and pathways for inhibiting nuclear hormonal receptor-negative and endocrine-resistant breast cancers.

1. Introduction

Current antihormonal therapies are frequently used for the treatment of hormone receptor positive breast cancers (i.e., estrogen receptor alpha and/or nuclear progesterone receptors, ER+ and/or PR+). For ER+ breast cancers, antiestrogen therapies (such as tamoxifen and anastrozole) are often effective, both in primary and in metastatic settings. The status of PR expression is used with ER to indicate potential effectiveness of antiestrogen therapies since the majority of breast cancers express ER and PR concurrently, even though PR may have independent predictive value for breast cancer [1, 2]. Previous studies with large-scale data sets found that ER+/PR− breast cancers do not respond as well as ER+/PR+ cancers to selective ER modulators [2]. It was proposed that patients with PR− breast cancer may receive a substantially better response from anastrozole rather than tamoxifen (compared to those with PR+ breast cancer) [1]. Synthetic progestin has been listed as a second line anticancer agent in “The NCCN Guidelines” (Version 1.2012 Breast Cancer, page 113). For example, megestrol acetate (MA) is used as an optional therapeutic agent for postmenopausal patients [3, 4] and medroxyprogesterone acetate (MPA) is often prescribed for treatment of metastatic breast cancer.
of membrane-bounded progesterone receptors. Recently, cell 30, 31]. This evidence lends strong support to the existence induced cell growth and migration of T47D cells, an ER+ protective effect on breast cancer cells [21]. For example, P4 of treatment, P4 can elicit either cancer promotion or cancer inhibition of cell proliferation by P4 [23], indicating that the effect of P4 on breast cancer cells in vitro. Depending upon the experimental cell model, cell context, and duration of treatment, P4 can elicit either cancer promotion or cancer protective effects on breast cancer cells [21]. For example, P4 induced cell growth and migration of T47D cells, an ER+ and PR+ human breast cancer cell line [22], but it inhibited proliferation of MDA-MB468 (MB468) cells, a human BPBC cell line with strong membrane progesterone receptor alpha (mPRα) expression [23]. In another human BPBC cell line MDA-MB231 (MB231), which was negative for both PR and mPRα receptors, P4 induced no response in cell proliferation. Introduction of mPRα cDNA into these cells rescued inhibition of cell proliferation by P4 [23], indicating that the P4 → mPRα signaling pathway played an essential role in controlling cell proliferation of human BPBC cells [23].

Progesterone exerts rapid nongenomic actions and these nonclassical actions usually take several minutes to half an hour to act [24, 25]. Extranuclear activity has been demonstrated for nuclear PR, especially PR-B, which involves the binding of the SH3 domain of Src and rapidly activates downstream MAPK/Erk1/2 [26]. P4 also exerts actions in cells and tissues naturally devoid of PR, such as T-lymphocytes, platelets, and rat corpus luteum [27–29]. Furthermore, potent PR agonist (i.e., R5020) and PR antagonist (i.e., RU486) showed little or no effect on P4's nongenomic actions [24, 30, 31]. This evidence lends strong support to the existence of membrane-bounded progesterone receptors. Recently, cell membrane hormonal receptors, such as mPR family (α, β, γ) and progesterone membrane receptor component-1 (PGMRC1), were demonstrated to be functional in breast cancer [32, 33]. It was reported that rapid responses are triggered by P4 binding to membrane receptors (i.e., mPRα) [34–36], subsequently inducing a series of alterations in secondary messenger pathways through activation of pertussis toxin-sensitive inhibitory G-proteins, to activate MAPK/Erk 1/2 pathway [32, 33, 37, 38]. We recently reported that the signaling cascade of P4 induced mesenchymal repression is mediated through caveolae bound signaling molecules, namely, Cav-1, EGFR, and PI3K. We also observed that one of the Src family kinase inhibitors [39–41] (4-amino-5-(4-methylphenyl)-7-(t-butyl)pyrazolo[3,4-d]-pyrimidin-5(4H)-one, or PP1) blocked the P4's action on expression of occludin and E-cadherin (epithelial phenotypes) but not on the expression of snail and fibronectin (one of the mesenchymal phenotypes) [23]. The roles of Src pathway in the P4/mPRα induced epithelial to mesenchymal transition (EMT) relevant signaling pathways remain to be explored in human BPBC cells.

Basal phenotype breast cancer (BPBC) is one of the most malignant breast cancers accounting for 15% of all breast cancers, and recent studies show that these cancers are often associated with brain metastasis [42, 43]. Unfortunately there is no well accepted mechanism that can explain how this brain metastatic potential is being developed in human BPBC cancers, and understanding this mechanism is essential for development of novel therapeutic tools for treatment of BPBC. MB231 is classified as a basal phenotype breast cancer cell line [44]. By a series of in vivo selections in mice, the populations with distinct brain metastatic tropisms were isolated [45, 46]. The brain metastatic derivative MB231 cell line (MB231Br) develops brain metastasis in 100% of mice and has served as the mainstay of most brain metastasis studies [47, 48]. It was reported that MB231Br cells have increased invasiveness through both Matrigel and blood-brain barrier (BBB) but decreased proliferation rate when compared with parental MB231 cells [49]. Genome-wide expression analysis suggested alternations in the gene expression profile of 243 genes in MB231Br cells as compared with the parent line [50]. In this study, we found that the expression of mPRα was upregulated in MB231Br cells and thus wondered if the upregulated mPRα is functional and can be used as a molecular target for modulating cell biological behavior of human BPBC cancers.

2. Material and Methods

2.1. Antibodies and Pathway Inhibitors. RU486 (MIF), AG1498, wortmannin, rapamycin, and pyrazolopyrimidine compound (PP1) were purchased from EMD Chemicals (Gibbstown, NJ, USA). BpV (phen) was from Thermo Fisher Scientific (Pittsburgh, PA, USA). Anti-mPRα goat polyclonal IgG, anti-MMP9 goat polyclonal IgG, anti-GAPDH goat polyclonal IgG, anti-mPRα blocking peptide, donkey anti-goat IgG-HRP, goat anti-rabbit IgG-HRP, and anti-mouse IgG were purchased from Santa Cruz Biotechnology (CA, USA). Anti-VEGF polyclonal antibody was from Abcom (Cambridge, MA, USA). Anti-KCNMA1 rabbit antibody was from Millipore (Billerica, MA, USA). Anti-FAK rabbit polyclonal and anti-p-FAK rabbit polyclonal IgG were from Cell Signaling (Danvers, MA, USA). P4-BSA-FITC conjugate and anti-α-tubulin mouse monoclonal IgM were purchased from Sigma (St. Louis, MO, USA).

2.2. Cell Culture. The human breast cancer cell lines MDA-MB468 (MB468) and MDA-MB231 (MB231) were obtained
from the American Type Culture Collection (Rockville, MD, USA). These cell lines are negative for ER, PR, and Her-2 and are classified as “basal phenotype A” breast cancer cells [15]. The brain seeking MB231 cell line (MB231Br) was a gift from Dr. Yoneda, which was established by six successive rounds of in vivo selection and ex vivo culture from parental MB231 cells [47]. These breast cancer cells were cultured in DMEM (Mediatech, VA, USA) containing 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin (Gibco, Carlsbad, CA, USA) in a humidified incubator at 37°C with 5% CO2.

2.3. Transfection of mPRα cDNA Plasmid. Transfection was performed as previously described [23]. Briefly, MB231 cells were cultured and split when the cell confluence reached approximately 90%. The human mPRα cDNA constructed in a pUC-based plasmid with CMV promoter (pBK-CMV) vector [30] was purified and then transfected into the cells using Lipofectamine 2000 reagent following the manufacturer’s instructions (Invitrogen, Carlsbad, CA, USA).

2.4. RT-PCR Assay. Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA, USA) and concentrations of RNA were determined using a NanoDrop 2000 Spectrophotometer (Thermo Scientific, USA). Reverse transcription for synthesizing cDNA was carried out using the Quantitect Reverse Transcription Kit (Qiagen, Valencia, CA, USA). PCR amplification (35 cycles of 95°C for 20 sec, 58°C for 30 sec, and 72°C for 20 sec) was conducted in a total volume of 25 μL using the GoTaq Hot Start Green Master Mix (Promega, Madison, WI, USA). Following PCR amplification, 25 μL of the samples was separated via electrophoresis on a 1.5% agarose gel. The primers used for PCR amplification were mPRα-(5′-CTGTTGATCTTAG-3′ and 5′-CGGAAAATAGAAACGGCCAG-3′) [31], 18-S-(5′-GGTGGTTTCCGAACCTGAGC-3′ and 5′-TGCAGGTCACTGTTATGCTG-3′) [51].

2.5. Immunoblotting Assay. Western blot assays were performed as described previously [23]. After treatment with or without P4 and/or diverse pathway inhibitors, the growth-arrested cells were lysed with 500 μL ice-cold lysis buffer (50 mM HEPES, 5 mM EDTA, 50 mM sodium chloride, pH 7.4), 1% Triton X-100, protease inhibitors (10 μg/mL aproatin, 1 mM phenylmethanesulfonyl fluoride, and 10 μg/mL leupeptin), and phosphatase inhibitors (50 mM sodium fluoride, 1 mM sodium orthovanadate, and 10 mM sodium pyrophosphate). Cell lysates (30 μg) were separated using SDS-PAGE and transferred to nitrocellulose membranes, blocked for one hour in TBS buffer containing 5% nonfat dry milk and 0.1% Tween 20, and incubated overnight with primary antibodies at proper dilutions. After incubation with secondary antibodies, proteins of interests were detected by ECL chemiluminescence. Image J (http://rsb.info.nih.gov/ij/) was used for image analysis and quantitative data was normalized with the reference proteins (i.e., GAPDH or α-tubulin) or calculated as ratios of phosphor protein/total protein when the reference proteins were the same.

2.6. Localization of P4-BSA-FITC Binding Sites on MB231Br Cells. Breast cancer cells were cultured in chamber slides and exposed to 100 nM P4-3-(O-carboxymethyl) oxime-BSA-FITC (P4-BSA-FITC) for 30 min in serum-depleted medium [24]. Cells were then washed with PBS buffer, fixed by 10% buffered formalin, counterstained with DAPI, and observed under a confocal microscope (Olympus FV1000, Tokyo, Japan) using an oil objective lens (×60).

2.7. Cell Proliferation Assay. Cell proliferation assay was performed using MTT kit (Invitrogen, CA, USA) [52]. Cells were seeded in a 96-well plate in 100 μL of culture medium with or without the compounds to be tested and incubated for 16 hrs at 37°C. MTT labeling reagent (1 μL of stock solution) was added to the designated wells and continually incubated for 4 hrs. The supernatant was removed and then 50 μL dimethyl sulfoxide (DMSO) was added. After shaking for 10 min at 37°C, the absorbance of each well was measured at a wavelength of 595 nm with a Bio-Tek microplate reader (Winooski, VT, USA). Experiments were designed in a triplicate format and cell proliferation rates were expressed as percentage proliferation compared to controls.

2.8. Wound Closure Migration Assay. Cells (5 × 10^4/well) were seeded in a 24-well plate and cultured to reach confluence and then scraped with a sterile micropipette tip to create a denuded zone (gap) with a constant width (T0). After removing cell debris with repeated PBS rinses, fresh serum-free DMEM medium with or without P4 (30 ng/mL) and/or other testing reagents were supplemented. Anti-mPRα antibody (1:200) and/or anti-mPRα blocking peptide (1:100) were added two hours before P4 treatment. PPI (10 μM), AG 1478 (1 μM), wortmannin (0.1 μM), rapamycin (10 nM), and BpV (phen) (1 μM) were added one hour before P4 treatment. The cells migrated at various speeds toward the middle axis from both edges of the scraped gaps, depending upon the treatment of aforementioned testing reagents, when they were incubated continually for 16 hours. After incubation, the width of the gap (T16hrs) was measured by Image J. The rate of wound closure (WC) was calculated by the following equation: WC = 1 – (T16hrs/T0) × 100% [53]; as referring control cells, migration inhibiting rate of treated cells (MIR) = 1 – (WCtreatment/WCcontrol) × 100%.

2.9. Invasion Assay. Cell invasion was assayed using the BD BioCoat Matrigel Invasion Chamber (BD Biosciences, MD, USA) [54]. Cells (4 × 10^4 cells/well) were seeded in the upper chamber of a 24-well BD transwell coated with Matrigel and cultured with DMEM medium containing 1% FBS. After treatment with P4 at 30 ng/mL for 24 hrs with or without PPI treatment at 10 μM for one hour, the complete medium was applied to the lower chamber as chemoattractant. Cells were washed by PBS and then incubated for additional 16 hrs and the cells in the upper surface of the chamber membrane were then carefully removed with a cotton swab. Cells that invaded into the lower surface of the membrane were fixed with 10% buffered formalin and stained with hematoxylin solution. The number of invading cells (IC)
from twenty random microscopic fields (×200 magnification) was counted. Invasion inhibition rate (IIR) was calculated as follows: IIR = 1 − (IC\textsubscript{treatment}/IC\textsubscript{control}) * 100%.

2.10. Statistical Analysis. The data was expressed as mean ± standard error (SE) and statistical differences between mean values were determined by Student’s paired two-tailed t-test, followed by Fisher’s protected least significance difference (PLSD). P < 0.05 was considered significant.

3. Results

3.1. Upregulation of mPR\textalpha Expression in the Brain Seeking MB231Br Cells. The brain seeking MB231Br cell line is increasingly used as a work horse model in brain metastatic studies, even though the molecular basis for its brain metastatic tropism is largely unknown [47, 48]. It was suggested that these cancer cells acquire the capacity to colonize brain in vivo following alternations in gene expression [47, 48]. In this study, we found that the expression of mPR\textalpha was upregulated from undetectable to moderately positive at both the transcriptional and translational levels. As shown in Figure 1(a), the designated PCR band for mPR\textalpha in MB231Br cells was clearly seen at a moderate level (line 1), while there was no band for the parent MB231 cells (line 2) and there were very strong bands for the mPR\textalpha cDNA transfected MB231 cells and MB468 cells (lines 3 and 4). Using cell lysates isolated from those cells, an identical pattern of mPR\textalpha protein expression was documented by Western blot assays (Figure 1(b)). To determine if mPR\textalpha protein in MB231Br cells is translocated to the membrane compartment, we performed in vitro binding tests using a cell impermeable P4 conjugate (P4-BSA-FITC). After a short incubation (30 min), we observed clear fluorescent signals in the membrane of MB231Br cells (white arrows, Figure 1(c)(A)). Similar fluorescent signals were also seen in the membrane of the mPR\textalpha transfected MB231 cells (Figure 1(c)(C)), but not in the parent MB231 cells (Figure 1(c)(B)). To further demonstrate the binding specificity, we coincubated MB231Br cells with P4-BSA-FITC conjugate and excessive unconjugated free P4. As shown in Figure 1(c)(D), no fluorescent signals were shown in MB231Br cells. Binding studies with the fluorescent probe P4-BSA-FITC, which cannot enter cells because of the bulk moiety of BSA, confirm the presence of progesterin-binding sites on the surface of cell membranes. This binding is specific because only free P4 was able to displace P4-BSA-FITC from breast cancer cells. This specificity was also confirmed by other studies that only unlabeled P4 human was able to substitute P4-BSA-FITC in pregnant myometrial cells in vitro whereas E2 and 11-deoxycortisone were ineffective [24, 25]. To study the function of mPR\textalpha receptor in MB231Br cells, we treated the cells with P4 at a series of concentrations (0, 30, and 60 ng/mL) for 48 hrs and demonstrated that the cell proliferation was inhibited in a dose dependent manner (Figure 2(a)). Cell morphological study showed that MB231Br cells without P4 incubation showed apparent mesenchymal phenotypes (Figures 2(b) and 2(c)), characterized by diverse sizes and spindle or elongated shapes, while, with P4 treatment, most of the cells showed epithelial-like phenotypes, featured by large and polygonal shapes or small oval shapes (Figures 2(d) and 2(e)).

3.2. Cell Migration of Human BPBC Cells in Response to Treatment of P4 and/or PP1. Further experiments were done
Figure 2: Effect of P4 on cell morphology and proliferation of MB231Br. (a) shows the results of cell proliferation assay of MB231Br and MB231 cells (*0.05 > P > 0.01). (b) and (c) show the cell morphology of MB231Br without P4 treatment; (d) and (e) show the cells treated by P4 (30 ng/mL and 60 ng/mL). Images were taken under confocal microscope (DIC) using ×40 oil objective lens.

to determine the effect of P4 treatment on cell migration. Using a wound closure assay, we found that the wound closure (WC) of MB231Br cells was slower (even though only marginally significant) when the cells were treated with P4 (30 ng/mL) for 16 hrs as compared to the cells without P4 treatment (40.6 ± 2.7% versus 50.0 ± 0.6%, MIR 18.9%, P_{WC} = 0.06, Figure 3). To explore the pathways that may be associated with P4’s effect, the cells were coincubated with P4 and/or a number of pathway inhibitors. As shown in Figure 3, the WC rate for cells treated by Src1 inhibitor (PP1) alone was minimally inhibited (MB231Br cells 35.7 ± 8.9% versus 50.0 ± 0.6%, MIR 28.5%, P_{WC} = 0.11), which was comparable to cells treated with P4 alone (P4 versus PP1 P = 0.46). Coincubation of P4 and PP1 resulted in a significant lower WC rate, as compared to the control (9.7 ± 4.5% versus 50.0 ± 0.6%, MIR 80.6%, P_{WC} = 0.01) or to P4 or PP1 treatment alone (P_{WC} = 0.007 or 0.02). In addition, coincubation of P4 and PP1 also caused the lowest WC rates in MB468 cells (16.7 ± 1.5%
versus 51.1 ± 1.5%, MIR 67.3%, \( P_{WC} = 0.001 \) and mPRα cDNA transfected MB231 cells (11.5 ± 0.6% versus 37.9 ± 2.9%, MIR 69.6%, \( P_{WC} \) value 0.009, Figure 3). In parental MB231 cells, neither P4 alone nor P4 in combination with PPI treatment showed significant changes in wound closure rates as compared to that of control (P4, PPI, and P4 + PPI versus control = 45.7 ± 0.6%, 44.8 ± 1.5%, and 43.3 ± 0.6% versus 45.6±2.3%, all \( P \) values > 0.05, Figure 3). These results indicated that P4 + PPI synergistically inhibit cell migration of mPRα+ human BPBC cells, namely, MB231Br, MB468, and mPRα cDNA transfected MB231 cells.

The mPRα expressing MB231Br cells were also treated with P4 and other pathway inhibitors, such as the EGFR inhibitor AG 1478 (51.7 ± 1.9%), PI3K inhibitor wortmannin (48.6 ± 0.5%), the mTOR inhibitor rapamycin (49.6 ± 1.2%), and the PTEN inhibitor (BpV (phen)) (47.8 ± 3.7%). There were no obvious WC differences observed as compared to controls (MIR were 2.2%, 3.8%, 1.7%, and 5.4%, \( P \) values were 0.80, 0.66, 0.84, and 0.63, respectively, Figure S1) (see Supplementary Material available online at http://dx.doi.org/10.1155/2014/426429).

3.3. MPRα and Its Role in Cell Migration of the Brain Seeking MB231Br Cells. In order to clarify the role of P4 → mPRα signaling in cell migration, we preincubated MB231Br cells with anti-mPRα antibody to block the binding of P4 to mPRα receptor one hour before P4 + PPI cotreatment. The inhibitory effects of P4 + PPI on cell migration were abrogated (WC 46.8 ± 3.3% versus 47.5 ± 3.7%, MIR1.5%, \( P_{WC} = 0.82 \)), indicating that mPRα receptor plays a key role

**Figure 3:** Effect of P4 + PPI on cell migration of human BPBC cells. The left panel shows the wound closure assays of MB231Br, MB231, MB468, and mPRα transfected MB231 cells (231 w/mPRα), with or without P4 and/or PPI treatments. Images were taken under confocal microscope using x10 objective lens. The right panel shows the summarized data from four independent assays (*0.05 > P > 0.01 and **P < 0.01*).
in P4 + PP1 induced cell migratory inhibition. When the cells were preincubated with anti-mPRα antibody and excess anti-mPRα blocking peptide, the inhibitory effects of P4 + PP1 on cell migration of MB231Br cells were restored (17.7 ± 2.3% versus 47.5 ± 3.7%, MIR 62.7%, \( P_{\text{WC}} = 0.001 \), Figure 4(a)).

### 3.4. Cell Invasion of the Brain Seeking MB231Br Cells in Response to P4 and/or PP1 Treatment.

As cancer invasion in vivo is a three-dimensional process involving transendothelial migration and penetration through extracellular matrix, a 3D cell invasion model could further delineate the role of P4 and/or PP1 on metastatic potential of MB231Br cells [55]. To assess the role of P4 and PP1 on cell invasion of MB231Br cells, a cell invasion assay was performed. After P4 and/or PP1 treatment for 16 hrs, the number of cells that invaded into the lower chamber of Matrigel (IC) was decreased as compared to control (71 ± 2 versus 125 ± 1 cells, IIR 43.2%, \( P < 0.001 \)), but treatment with either P4 or PP1 alone was ineffectual (121 ± 4 and 116 ± 1 cells, IIR 3.2% and 7.2%; \( P_{\text{IC}} \) values were 0.61 and 0.22). In parent MB231 cells, there were no obvious IC changes with or without P4 and/or PP1 treatment, as expected (Figure 4(b)).

### 3.5. Neither Nuclear PR Nor PGRMC1 Plays a Key Role in Mediating P4 + PP1’s Inhibitory Effects on Cell Migration of MB231Br Cells.

The expression of PR in basal phenotype breast cancer cells (i.e., MB468 cells) may be induced by P4 treatment, even though the extent of induction is very low [23]. To clarify if induction of endogenous PR expression has a role in the P4 induced cell migratory inhibition, we preincubated MB231Br cells with MIF, a PR antagonist, before P4 and/or PP1 treatment. It was found that wound closure rates were not affected after P4 and/or PP1 treatment (P4 versus MIF + P4, PP1 versus MIF + PP1, and P4 + PP1 versus MIF + P4 + PP1 were **38.9±1.8**% versus **35.3±5.1**%, **26.6±4.2**% versus **36.1±5.6**%, and **9.7±4.5**% versus **14.2±4.9**%; all \( P_{\text{WC}} \) values > 0.05, Figure 5(a)).

In addition to mPRα, PGRMC1 has been implicated in membrane-initiated progesterone signaling [56]. It is unclear whether mPRα functions alone or requires PGRMC1 as a co-regulator. In a Western blot assay, the protein expression of PGRMC1 from MB231Br cells was minimally affected with P4 and/or PP1 treatment (Figure 5(b)). We then preincubated MB231Br cells with PGRMC1 antibody to block or interfere with the function of...
Figure 5: (a) Effect of P4 + PP1 on cell migration of MB231Br in presence of MIF. The up panels of (a) show the wound closure assays of MB231Br and MB231 cells with or without P4 and/or PP1 treatments as indicated. All of the cells were preincubated with MIF. Images were taken under confocal microscope using ×10 objective lens. The lower panel of (a) shows the summarized data from two independent assays (*0.05 > P > 0.01). (b) Effect of P4 + PP1 on cell migration of MB231Br in presence of anti-PGRMC1 antibody. Growth-arrested MB231Br and MB231 cells were treated with or without P4 and/or PP1 treatment as indicated. Western blot assays for evaluating PGRMC1 expression were performed. The up panel of (b) shows the representative image from three Western blot assays. The middle panel of (b) shows the wound closure assays of MB231Br cells with or without P4 and/or PP1 treatments as indicated. Images were taken under confocal microscope using ×10 objective lens. The graph in the bottom of (b) shows the summarized data from four independent assays (*0.05 > P > 0.01, ** P < 0.01).
PGRMC1 protein one hour before P4 and/or PP1 treatment. The wound closure rates, in the presence of anti-PGRMC1 antibody, demonstrated no change on cell migration pattern as compared to those induced by P4 alone or by P4 + PP1 (WC 15.2 ± 6.1% and 10.2 ± 1.4% versus 37.3 ± 3.4%, P values were 0.047 and 0.008, resp.). Treatment of anti-PGRMC1 antibody alone had no effect on cell migration (37.8 ± 4.3% versus 37.3 ± 3.4%, P = 0.93).

3.6. Molecular Pathways Involved in the P4 + PP1 Inhibited Cell Migration of MB231Br Cells. Based upon the results of cell migration assays, synergistic effect of P4 and PP1 on cell migration and invasion of MB231Br cells was suggested. Moreover, P4 has been reported to signal via Src family kinases for the formation of focal adhesion complex via focal adhesion kinase (FAK, a key component for tumor metastasis) phosphorylation at Tyr (397) [57]. To confirm the molecular mechanisms underlying P4 + PP1’s action, we evaluated the phosphorylation of Src and FAK using Western blot assay. It was found that the level of phosphor-FAK in MB231Br cells was inhibited by P4 + PP1 treatment significantly (as compare to that of control, 43.6% versus 100%, P = 0.009), while the status of Src phosphorylation was not changed by P4 + PP1 cotreatment. P4 or PP1 treatment alone did not change the levels of phosphor-FAK in MB231Br cells (94.6%, 81.1% versus 100%, all P values > 0.05) (Figure 6(a)). We also investigated the effect of P4 and/or PP1 on expression of other selected cancer metastasis relevant proteins, such as MMP9, VEGF, and KCNMA1 [58]. The expression levels of MMP9 (79.3% versus 100%, P = 0.009), VEGF (33.2% versus 100%, P = 0.04), and KCNMA1 (77.6% versus 100%, P = 0.02) were reduced by P4 + PP1 cotreatment in MB231Br cells remarkably but again not by P4 or PP1 individual treatments as compared to controls (All P values > 0.05, Figure 6(b)).

4. Discussion

4.1. Upregulation of MPRα May Contribute to the Brain Metastatic Tropism of MB231Br Cells. The role of progesterone (P4) in breast cancer development has attracted substantial interest. It is believed that the physiological action of P4 is mediated through either nuclear PR or membrane-bound receptors. In this study, using RT-PCR and Western blotting assays, we first showed the expression of mPRα in the membrane of MB231Br cells, a functional site of this hormonal receptor. To study the function of mPRα in MB231Br cells, we demonstrated that P4 treatment inhibits cell proliferation (Figure 2(a)) and reverses cell morphology from mesenchymal phenotypes to epithelial-like phenotypes (Figures 2(b)–2(d)), while in mPRα negative MB231 cells P4 treatment had no effect. These results were consistent with our previous results on MB468 cells [23]. Khan et al. performed a genomewide expression profiling on two human BPBC cell lines—parental MB231 and brain seeking MB231Br cells [59]. They found elevated levels of genes that promote cell motility and invasion, while genes that prevent cancer metastasis were downregulated in MB231Br cells (compared to parental MB231 cells) [60–62]. Bos et al. compared the gene expression profiles of the brain seeking cells from MDA-MB-231 and CN34 cells from the tumor of an ER-patient [50]. They found 243 genes differentially expressed between the brain metastasis and parental cell lines. Of those, the expression of 17 genes was correlated with brain relapse in patient samples without association with bone, liver, or lymph node metastasis [63]. It was assumed that these altered gene expression profiles acquainted from a series of in vivo/ex vivo selections may facilitate the successful colonization in brain.

4.2. MPRα May Serve as a Key Mediator for P4’s Action on Cell Migratory and Invasion Inhibition in MB231Br Cells. Progesterone is known to play a profound role in breast cancer cell migration. In this study, we showed that P4 treatment alone can slightly inhibit, rather than enhance, the cell migration of MB231Br cells; more interestingly, treatment of P4 plus PP1 can significantly inhibit cell migration of MB231Br cells. Since PP1 treatment alone inhibited cell migration only at a moderate level, which was comparable to P4, we assumed that combinational treatment with both can synergize the molecular signal magnitude and vigorously inhibit cell migration in vitro. Similarly, in cell invasion assay, synergistic results were also obtained from the cells which were treated by P4 + PP1 (IIR 43.2%) but not by P4 or PP1 alone (IIR = 3.2% and 7.2%), while Fu et al. found that cell migration and invasion were both enhanced by all the P4 and its derivatives tested in T47-D cells (ER+/PR+) [64, 65]. Different results may be due to various cell lines with different PR and ER expression.

Since parent MB231 cells do not contain full-length or C-terminus PRs [66], we assumed that the acquired expression of mPRα may serve as a key mediator for P4’s action in MB231Br cells. This assumption was supported by the following findings. (1) Block the binding of P4 to mPRα receptor by preincubating MB231Br cells with anti-mPRα antibody, which abrogated the inhibitory effects of P4 + PP1 on cell migration. Preincubating the cells with anti-mPRα antibody and excess anti-mPRα blocking peptide, the inhibitory effects of P4 + PP1 on cell migration were unaffected. These results indicated that the role of mPRα in cell migration and regulation is essential. (2) P4 treatment may upregulate PR expression in human BPBC cells (e.g., MB231 cells) [23, 67], which could mediate the effect of P4. To exclude the potential role of PR in this study, we preincubated the cells with MIF, a P4 antagonist, and found that it did not affect P4’s and/or PP1’s effects on MB231Br cell migration. (3) PGRMC1 is required for some aspects of P4 signaling in estrogen receptor-negative breast tumors through an unidentified mechanism [68, 69]. Thomas et al. demonstrated that overexpression of human PGRMC1 in nuclear PR negative breast cancer cell lines causes increased expression of mPRα on cell membranes and increased specific P4 binding [70]. To exclude the potential role of PGRMC1 in this study, we demonstrated that P4 and/or PP1 treatment had no effect on PGRMC1 expression in MB231Br cells, as compared to that in vehicle treated control cells. In addition, coincubating the MB231Br cells with anti-PGRMC1 antibody and P4 and/or PP1 did not affect the cell migration patterns. These results suggested that PGRMC1 and its signaling pathways
Figure 6: Effect of P4 + PP1 on FAK phosphorylation and expression of MMP-9 and KCNMA1 in MB231Br cells. Growth-arrested MB231Br and MB231 cells were treated with or without P4 and/or PP1 treatment as indicated. Western blot assays for evaluating the status of Src and FAK phosphorylation and expression of MMP-9, VEGF, and KCNMA1 were performed with proper antibodies. The upper panel shows the representative image from three Western blot assays. The graph in the bottom shows the summarized data from three independent assays (*0.05 > P > 0.01).

may not be involved in the roles of P4 and PP1 on cell migration.

4.3. Molecular Pathways Involved in P4 + PP1/mPRα Signaling. Progesterone exerts rapid nongenomic actions which are triggered by P4 binding to mPRα [34–36] and subsequently induces a series of alterations in secondary messenger pathways through activation of pertussis toxin-sensitive inhibitory G-proteins, to activate MAPK/Erk 1/2 pathway [32, 33, 37, 38]. We recently reported that the signaling cascade of P4 induced mesenchymal repression of human BPBC cells through caveolae bound signaling molecules, namely, Cav-1, EGFR, and PI3K. We also observed that the Src family kinase inhibitor (PP1) blocked the P4’s action on proteins that control cell epithelial differentiation but not on the proteins that control cell mesenchymal differentiation. Src has been reported to be a starting point for many biochemical cascades and exerts a profound effect on focal adhesion systems and cytoskeleton reorganization and thereby influences cancer cell migration and invasion as well as other tumor progression-related events [71]. In this report, we showed that P4 + PP1 (a Src family inhibitor [72, 73]) synergistically inhibited the cell migration of the mPRα expressing MB231Br cells significantly. Focal adhesion
kinase (FAK) is a downstream component of Src signaling pathway controlling cell motility [74]. Through multifaceted molecular connections, FAK controls cell movement by regulating the cytoskeleton structures, cell adhesion sites, and membrane protrusions [74, 75]. In presence of PR, P4 could induce the phosphorylation and activation of FAK [76]. For example, MB231 breast cancer cells transfected with PR were exposed to P4 and displayed an increased expression of phosphorylated FAK and formation of FA complexes, which led to an enhanced cell migration and invasion [76].

In human BPBC cell models, which are depleted of nuclear PR but mPRα positive, P4 and PPI cotreatment induced significant FAK dephosphorylation (rather than phosphorylation), while P4 or PPI individual treatment did not affect the status of FAK. This may explain the diverse roles of P4 in different human BPBC and non-BPBC cancer cells. Also, the roles of other pathway inhibitors on cell migration of MB231Br cells were also tested. Cotreatment of these cells with P4 and EGFR inhibitor (AG1478) or PI3K inhibitor (wortmannin) or mTOR inhibitor (rapamycin) and/or PTEN inhibitor (BpV (phen)) had no obvious WC differences observed as compared to controls (Figure S1).

To determine the downstream effector protein molecules of Src/FAK pathway, we studied metastatic relevant protein expression profiles. Matrix metalloproteinases (MMPs) and VEGF have been implicated in several aspects of tumor progression, such as invasion through basement membrane and interstitial matrices, angiogenesis, and tumor cell growth. In the present study, we found that MB231Br cells express MMP-9 and VEGF at comparable levels as that of MB231 cells. In response to P4 or PPI treatment alone, the expression of MMP9 and VEGF in MB231Br cells exhibited minimal changes; however, combination treatment with both induced significant reduction in MMP9 and VEGF expression, a similar pattern as that of FAK dephosphorylation, supporting these prometastatic proteins as the downstream effectors of Src/FAK pathway. KCNMA1 (large conductive calcium-activated potassium channel (BKCa)) [77]. KCNMA1 expression was reported in metastatic breast cancer cells and increased BKCa channel activity might associate with greater invasiveness and transendothelial migration [58]. It was assumed that the relative abundance of BKCa channel expression in brain metastatic breast cancer may provide a unique opportunity to identify breast tumors that are at high risk for brain metastasis [58]. In this study, we found that KCNMA1 expression was also inhibited in MB231Br cells in a similar pattern as compared with that of FAK dephosphorylation and MMP9 expression in response to P4 and/or PPI treatment. We assumed that MMP-9 and KCNMA1 serve as terminal effects of the Src/FAK signal pathway.

5. Conclusions

In summary, using brain seeking MB231Br cells and other human BPBC cell lines as models, we identified an mPRα mediated pathway that involves Src/FAK and a chain of downstream cell signaling components. This molecular pathway could be inhibited by incubating MB231Br cells with P4 and PPI concurrently. It was assumed that PPI enhances the P4’s effect on FAK dephosphorylation, MMP9, VEGF, and KCNMA1 downregulation and eventually inhibits cell migration synergistically. Our study has provided a mechanistic view on the effects of P4 as a promising physiological anticancer agent, through mPRα → Src/FAK relevant signal transduction pathways in human BPBC cells.

Abbreviations

BPBC: Basal phenotype breast cancers
P4: Progesterone
MB468: MDA-MB468 cells
EMT: Epithelial-mesenchymal transition
mPRα: Membrane progesterone receptor α
MB231: MDA-MB231 cells
PRs: Progesterone receptors
ATCC: American Type Culture Collection
IHC: Immunohistochemistry
TNBC: Triple negative cancers.

Conflict of Interests

The authors declare that they have no competing interests.

Acknowledgments

The authors thank Dr. Peter Thomas (Marine Science Institute, University of Texas at Austin) for providing mPRα plasmid and kind consultancy and Dr. Hima Bindu Chunduri and Dr. Prem Sharma (Atlanta Research & Educational Foundation, Atlanta VA Medical Center, GA) for their assistance in plasmid DNA isolation. This study was supported by the Emory University Research ACTSI Award (S. You), Atlanta Research and Education Foundation Bridge Fund (S. You), and China Scholarship Council and Central South University (Mingxuan Xie and Qiong Chen).

References

[1] M. T. Weigel and M. Dowsett, “Current and emerging biomarkers in breast cancer: prognosis and prediction,” Endocrine-Related Cancer, vol. 17, no. 4, pp. R245–R262, 2010.
[2] X. Cui, R. Schiff, G. Arpino, C. K. Osborne, and A. V. Lee, “Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy,” Journal of Clinical Oncology, vol. 23, no. 30, pp. 7721–7735, 2005.
[3] J. Alexieva-Figusch, H. A. van Gilse, W. C. J. Hop, C. H. Phoa, J. Blank-van der Wijst, and R. E. Treurniet, “Progestin therapy in advanced breast cancer: megestrol acetate: an evaluation of 160 treated cases,” Cancer, vol. 46, no. 11, pp. 2369–2372, 1980.
[4] P. A. Johnson, H. Muss, P. Bonomi et al., “Megestrol acetate as primary hormonal therapy for advanced breast cancer,” Seminars in Oncology, vol. 15, supplement 1, no. 2, pp. 34–37, 1988.
[5] R. Nishimura, K. Nagao, M. Matsuda et al., “Predictive value of serum medroxyprogesterone acetate concentration for...
response in advanced or recurrent breast cancer,” European Journal of Cancer Part A, vol. 33, no. 9, pp. 1407–1412, 1997.

[6] S. Otani, N. Toyota, K. Nozaka et al., “Successful combination therapy with 5'-DFUR and MPA for breast cancer with spinal and vertebral metastases,” Gan to Kagaku Ryoho, vol. 31, no. 13, pp. 2151–2153, 2004.

[7] T. Otsuka, Y. Terashima, and S. Tashiro, “A case of long surviving advanced recurrent breast cancer with multiple bone metastases responding to treatment with 5'-DFUR combined with MPA,” Gan To Kagaku Ryoho, vol. 29, no. 2, pp. 313–316, 2002.

[8] R. Zaucha, K. Sosińska-Mielcarek, and J. Jassem, “Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate,” Breast, vol. 13, no. 4, pp. 321–324, 2004.

[9] T. Toyama, H. Yamashita, Y. Hara, Y. Hikosaka, S. Kobayashi, and H. Iwase, “Successful management of breast cancer with liver metastases with medroxyprogesterone acetate treatment,” International Journal of Clinical Oncology, vol. 6, no. 6, pp. 306–309, 2001.

[10] H. Mio, “A case of postoperative recurrent breast cancer with multiple lung metastases that completely responded to combination therapy of docetaxel (TXT) and medroxyprogesterone acetate (MPA),” Cancer & Chemotherapy, vol. 30, no. 7, pp. 985–988, 2003.

[11] D. Generali, F. M. Buffa, A. Berruti et al., “Phosphorylated ERα, HIF-1α, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer,” Journal of Clinical Oncology, vol. 27, no. 2, pp. 227–234, 2009.

[12] P. Thomas, C. Tubbs, and V. F. Garry, “Progestin functions in vertebrate gametes mediated by membrane progestin receptors (mPRs): Identification of mPRα on human sperm and its association with sperm motility,” Steroids, vol. 74, no. 7, pp. 614–621, 2009.

[13] L. S. Cooper, C. E. Gillett, N. K. Patel, D. M. Barnes, and I. S. Fentiman, “Survival of premenopausal breast carcinoma patients in relation to menstrual cycle timing of surgery and estrogen receptor/progesterone receptor status of the primary tumor,” Cancer, vol. 86, no. 10, pp. 2053–2058, 1999.

[14] Z. Saad, V. Bramwell, J. Duff et al., “Timing of surgery in relation to the menstrual cycle in premenopausal women with operable breast cancer,” British Journal of Surgery, vol. 81, no. 2, pp. 217–220, 1994.

[15] K. Bove, D. W. Lincoln, P. A. Wood, and W. J. M. Hrushesky, “Fertility cycle influence on surgical breast cancer cure,” Breast Cancer Research and Treatment, vol. 75, no. 1, pp. 65–72, 2002.

[16] W. J. M. Hrushesky, S. A. Gruber, R. B. Sothern et al., “Natural killer cell activity: age, estrous- and circadian-stage dependence and inverse correlation with metastatic potential,” Journal of the National Cancer Institute, vol. 80, no. 15, pp. 1232–1237, 1988.

[17] L. Sivaraman and D. Medina, “Hormone-induced protection against breast cancer,” Journal of Mammary Gland Biology and Neoplasia, vol. 7, no. 1, pp. 77–92, 2002.

[18] D. Medina, “Mammary developmental fate and breast cancer risk,” Endocrine-Related Cancer, vol. 12, no. 3, pp. 483–495, 2005.

[19] J. E. Rossouw, G. L. Anderson, R. L. Prentice et al., “Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial,” Journal of the American Medical Association, vol. 288, no. 3, pp. 321–333, 2002.

[20] G. L. Anderson, M. Limacher, A. R. Assaf et al., “Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial,” JAMA, vol. 291, no. 14, pp. 1701–1712, 2004.

[21] C. A. Lange, J. K. Richer, and K. B. Horwitz, “Hypothesis: progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals,” Molecular Endocrinology, vol. 13, no. 6, pp. 829–836, 1999.

[22] E. M. McGowan, S. Saad, L. J. Bendall, K. F. Bradstock, and C. L. Clarke, “Effect of progesterone receptor A predominance on breast cancer cell migration into bone marrow fibroblasts,” Breast Cancer Research and Treatment, vol. 83, no. 3, pp. 211–220, 2004.

[23] L. Zuo, W. Li, and S. You, “Progesterone reverses the mesenchymal phenotypes of basal phenotype breast cancer cells via a membrane progesterone receptor mediated pathway,” Breast Cancer Research, vol. 12, article R34, 2010.

[24] E. Karteris, S. Zervou, Y. Pang et al., “Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term,” Molecular Endocrinology, vol. 20, no. 7, pp. 1519–1534, 2006.

[25] C. Tubbs and P. Thomas, “Progestin signaling through an olfactory G protein and membrane progesterin receptor-α in Atlantic croaker sperm: potential role in induction of sperm hypermotility,” Endocrinology, vol. 150, no. 1, pp. 473–484, 2009.

[26] V. Boonyaratanakornkit, E. McGowan, L. Sherman, M. A. Mancini, B. J. Chesiks, and D. P. Edwards, “The role of extranuclear signaling actions of progesterone receptor in mediating progesterone regulation of gene expression and the cell cycle,” Molecular Endocrinology, vol. 21, no. 2, pp. 359–375, 2007.

[27] G. R. Ehring, H. H. Kerschbaum, C. Eder et al., “A nongenomic mechanism for progesterone-mediated immunosuppression: inhibition of K⁺ channels, Ca²⁺ signaling, and gene expression in T lymphocytes,” The Journal of Experimental Medicine, vol. 188, no. 9, pp. 1593–1602, 1998.

[28] R. Colomer, S. Montero, A. Lluch et al., “Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer,” Clinical Cancer Research, vol. 6, no. 6, pp. 2356–2362, 2000.

[29] O.-K. Park-Sarge, T. G. Parmer, Y. Gu, and G. Gibori, “Does the rat corpus luteum express the progesterone receptor gene?” Endocrinology, vol. 136, no. 4, pp. 1537–1543, 1995.

[30] P. Thomas, Y. Pang, J. Dong et al., “Steroid and G protein binding characteristics of the seaturt and human prostegin membrane receptor α subtypes and their evolutionary origins,” Endocrinology, vol. 148, no. 2, pp. 705–718, 2007.

[31] C. Dosiou, A. E. Hamilton, Y. Pang et al., “Expression of membrane progesterone receptors on human T lymphocytes and Jurkat cells and activation of G-proteins by progesterone,” Journal of Endocrinology, vol. 196, no. 1, pp. 67–77, 2008.

[32] P. Thomas, “Characteristics of membrane progesterin receptor alpha (mPRalpha) and progesterone membrane receptor component 1 (PGMRC1) and their roles in mediating rapid progestin actions,” Frontiers in Neuroendocrinology, vol. 29, no. 2, pp. 292–312, 2008.

[33] G. E. Dressing and P. Thomas, “Identification of membrane progesterin receptors in human breast cancer cell lines and biopsies and their potential involvement in breast cancer,” Steroids, vol. 72, no. 2, pp. 111–116, 2007.

[34] E. Falkenstein, H.-C. Tillmann, M. Christ, M. Feuring, and M. Wehling, “Multiple actions of steroid hormones—a focus on rapid, nongenomic effects,” Pharmacological Reviews, vol. 52, no. 4, pp. 513–555, 2000.
[35] R. Lösel and M. Wehling, “Nongenomic actions of steroid hormones,” Nature Reviews Molecular Cell Biology, vol. 4, no. 1, pp. 46–56, 2003.

[36] R. Lösel, S. Breiter, M. Seyfert, M. Wehling, and E. Falkenstein, “Classic and non-classic progesterone receptors are both expressed in human spermatogonia,” Hormone and Metabolic Research, vol. 37, no. 1, pp. 10–14, 2005.

[37] N. Sleiter, Y. Pang, C. Park et al., “Progesterone receptor A (PRA) and PRB-independent effects of progesterone on gonadotropin-releasing hormone release,” Endocrinology, vol. 150, no. 8, pp. 3833–3844, 2009.

[38] Y. Zhu, C. D. Rice, Y. Pang, M. Pace, and P. Thomas, “Cloning, expression, and characterization of a membrane progesterin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 5, pp. 2231–2236, 2003.

[39] W. Xu, X. Yuan, Y. J. Jung et al., “The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PI3K phosphatase-independent inactivation of Akt in ErbB2 overexpressing breast cancer cells,” Cancer Research, vol. 63, no. 22, pp. 7777–7784, 2003.

[40] Y. Hirokawa, A. Levitzki, G. Lessene et al., “Signal therapy of human pancreatic cancer and NFI-deficient breast cancer xenograft in mice by a combination of PPI and GL–2003, anti-PASKi drugs (Tyr-kinase inhibitors),” Cancer Letters, vol. 245, no. 1-2, pp. 242–251, 2007.

[41] A. C. Bishop, C.-Y. Kung, K. Shah, L. Witucki, K. M. Shokat, and Y. Liu, “Generation of monospecific nanomolar tyrosine kinase inhibitors via a chemical genetic approach,” Journal of the American Chemical Society, vol. 121, no. 4, pp. 627–631, 1999.

[42] S. Cleator, W. Heller, and R. C. Coombes, “Triple-negative breast cancer: therapeutic options,” The Lancet Oncology, vol. 8, no. 3, pp. 235–244, 2007.

[43] N. U. Lin, E. Claus, J. Sohl, A. R. Razzaq, A. Arnaout, and E. P. Winer, “Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases,” Cancer, vol. 113, no. 10, pp. 2638–2645, 2008.

[44] R. M. Neve, K. Chin, J. Fridlyand et al., “A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes,” Cancer Cell, vol. 10, no. 6, pp. 515–527, 2006.

[45] Y. Kang, P. M. Siegel, W. Shu et al., “A multigenic program mediating breast cancer metastasis to bone,” Cancer Cell, vol. 3, no. 6, pp. 537–549, 2003.

[46] A. J. Minn, G. P. Gupta, P. M. Siegel et al., “Genes that mediate breast cancer metastasis to lung,” Nature, vol. 436, no. 7050, pp. 518–524, 2005.

[47] T. Yoneda, P. J. Williams, T. Hiraga, M. Niewolna, and R. Nishimura, “A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro,” Journal of Bone and Mineral Research, vol. 16, no. 8, pp. 1486–1495, 2001.

[48] R. J. Weil, D. C. Palmieri, J. L. Bronder, A. M. Stark, and P. S. Steeg, “Breast cancer metastasis to the central nervous system,” The American Journal of Pathology, vol. 167, no. 4, pp. 913–920, 2005.

[49] E. I. Chen, J. Havel, J. S. Krueger et al., “Adaptation of energy metabolism in breast cancer brain metastases,” Cancer Research, vol. 67, no. 4, pp. 1472–1486, 2007.

[50] P. D. Bos, X. H. Zhang, C. Nadal et al., “Genes that mediate breast cancer metastasis to the brain,” Nature, vol. 459, no. 7249, pp. 1005–1009, 2009.

[51] V. T. Ciavatta, M. Kim, P. Wong et al., “Retinal expression of Fgf2 in RCS rats with subretinal microphotodiode array,” Investigative Ophthalmology & Visual Science, vol. 50, no. 10, pp. 4523–4530, 2009.

[52] L. Min, Q. Chen, S. He, S. Liu, and Y. Ma, “Hypoxia-induced increases in A549/CDDP cell drug resistance are reversed,” Molecular Medicine Reports, vol. 5, no. 1, pp. 228–232, 2012.

[53] N. Dhanesuan, J. A. Sharp, T. Blick, J. T. Price, and E. W. Thompson, “Doxycycline-inducible expression of SPARC/Osteonectin/BRM40 in MDA-MB-231 human breast cancer cells results in growth inhibition,” Breast Cancer Research and Treatment, vol. 75, no. 1, pp. 73–85, 2002.

[54] B. Desai, T. Ma, and M. A. Chelliah, “Invadopodia and matrix degradation, a new property of prostate cancer cells during migration and invasion,” The Journal of Biological Chemistry, vol. 283, no. 20, pp. 13856–13866, 2008.

[55] C. Cougoule, V. Le Cabec, R. Poincloux et al., “Three-dimensional migration of macrophages requires Hck for podosome organization and extracellular matrix proteolysis,” Blood, vol. 115, no. 7, pp. 1444–1452, 2010.

[56] H. Neubauer, Y. Yang, H. Seeger et al., “The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells,” Menopause, vol. 18, no. 8, pp. 845–850, 2011.

[57] X.-D. Fu, L. Goglia, A. M. Sanchez et al., “Progesterone receptor enhances breast cancer cell motility and invasion via extranuclear activation of focal adhesion kinase,” Endocrine-Related Cancer, vol. 17, no. 2, pp. 431–443, 2010.

[58] D. Khaitan, U. T. Sankpal, B. Weksler et al., “Role of KCNMA1 gene in breast cancer invasion and metastasis to brain,” BMC Cancer, vol. 9, article 258, 2009.

[59] J. Khan, L. H. Saal, M. L. Bittner, Y. Chen, J. M. Trent, and P. S. Meltzer, “Expression profiling in cancer using cDNA microarrays,” Electrophoresis, vol. 20, no. 2, pp. 223–229, 1999.

[60] A. M. Stark, B. Anuszkiewicz, R. Mentlein, T. Yoneda, and R. Mentlein, “Endoglin expression in metastatic MDA-MB-231 breast cancer cells,” Oncogene, vol. 28, no. 1, pp. 228–232, 2012.

[61] D. Oxmann, J. Held-Feindt, “Reduced metastasis-suppressor gene mRNA results in growth inhibition,” BMC Cancer, vol. 8, article 166, 2008.

[62] A. M. Stark, K. Tongers, N. Maass, H. M. Mehdorn, and J. Held-Feindt, “Differential expression of matrix metalloproteinases in brain- and bone-seeking clones of metastatic MDA-MB-231 breast cancer cells,” Journal of Neuro-Oncology, vol. 81, no. 1, pp. 39–48, 2007.

[63] D. Oxmann, J. Held-Feindt, A. M. Stark, K. Hattermann, T. Yoneda, and R. Mentlein, “Endoglin expression in metastatic breast cancer cells enhances their invasive phenotype,” Oncogene, vol. 27, no. 25, pp. 3567–3575, 2008.

[64] A. M. Stark, K. Tongers, N. Maass, H. M. Mehdorn, and J. Held-Feindt, “Reduced metastasis-suppressor gene mRNA expression in breast cancer brain metastases,” Journal of Cancer Research and Clinical Oncology, vol. 131, no. 3, pp. 191–198, 2005.

[65] A. J. Minn, G. P. Gupta, D. Padua et al., “Lung metastasis genes couple breast tumor size and metastatic spread,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 16, pp. 6740–6745, 2007.

[66] X.-D. Fu, M. S. Giretti, L. Goglia et al., “Comparative actions of progesterone, medroxyprogesterone acetate, drospirenone and nestorone on breast cancer cell migration and invasion,” BMC Cancer, vol. 8, article 166, 2008.

[67] X.-D. Fu, M. S. Giretti, C. Baldacci et al., “Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton,” PLoS ONE, vol. 3, no. 7, Article ID e2790, 2008.
[66] Y. Pang and P. Thomas, “Progesterone signals through membrane progesterone receptors (mPRs) in MDA-MB-468 and mPR-transfected MDA-MB-231 breast cancer cells which lack full-length and N-terminally truncated isoforms of the nuclear progesterone receptor,” Steroids, vol. 76, no. 9, pp. 921–928, 2011.

[67] K. B. Horwitz, W. W. Dye, J. C. Harrell, P. Kabos, and C. A. Sartorius, “Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 15, pp. 5774–5779, 2008.

[68] R. J. Craven, “PGRMC1: a new biomarker for the estrogen receptor in breast cancer,” Breast Cancer Research, vol. 10, no. 6, article 113, 2008.

[69] H. Neubauer, S. E. Clarke, W. Wozny et al., “Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1,” Breast Cancer Research, vol. 10, no. 5, article R85, 2008.

[70] P. Thomas, Y. Pang, and J. Dong, “Enhancement of cell surface expression and receptor functions of membrane progestin receptor α (mPRα) by progesterone receptor membrane component 1 (PGRMC1): evidence for a role of PGRMC1 as an adaptor protein for steroid receptors,” Endocrinology, vol. 155, no. 3, pp. 1107–1119, 2014.

[71] M. Guarino, “Src signaling in cancer invasion,” Journal of Cellular Physiology, vol. 223, no. 1, pp. 14–26, 2010.

[72] J. H. Hanke, J. P. Gardner, R. L. Dow et al., “Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation,” The Journal of Biological Chemistry, vol. 271, no. 2, pp. 695–701, 1996.

[73] R. Karni, S. Mizrahi, E. Reiss-Sklan, A. Gazit, O. Livnah, and A. Levitzki, “The pp60c-src inhibitor PP1 is non-competitive against ATP,” FEBS Letters, vol. 537, no. 1–3, pp. 47–52, 2003.

[74] S. K. Mitra, D. A. Hanson, and D. D. Schlaepfer, “Focal adhesion kinase: in command and control of cell motility,” Nature Reviews Molecular Cell Biology, vol. 6, no. 1, pp. 56–68, 2005.

[75] J. J. Acosta, R. M. Muñoz, L. González et al., “Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathways,” Molecular Endocrinology, vol. 17, no. 11, pp. 2268–2282, 2003.

[76] V. C. Lin, E. H. Ng, S. E. Aw, M. G. Tan, E. H. Ng, and B. H. Bay, “Progesterone induces focal adhesion in breast cancer cells MDA-MB-231 transfected with progesterone receptor complementary DNA,” Molecular Endocrinology, vol. 14, no. 3, pp. 348–358, 2000.

[77] X. Liu, Y. Chang, P. H. Reinhart, and H. Sontheimer, “Cloning and characterization of glioma BK, a novel BK channel isoform highly expressed in human glioma cells,” The Journal of Neuroscience, vol. 22, no. 5, pp. 1840–1849, 2002.